-
EP4081805
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4081805
| EP4081805 - METHODS OF TREATING PREGNANCY-ASSOCIATED ATYPICAL HEMOLYTIC UREMIC SYNDROME USING AN ANTI-C5 ANTIBODY [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 30.09.2022 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 07.07.2021 | ||
| Former | unknown Status updated on 26.01.2021 | Most recent event Tooltip | 27.12.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Alexion Pharmaceuticals, Inc. 121 Seaport Boulevard Boston, MA 02210 / US | [2022/44] | Inventor(s) | 01 /
DENKER, Andrew 119 Bleddyn Road Ardmore, PA 19003 / US | [2022/44] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2022/44] | Application number, filing date | 20842123.0 | 18.12.2020 | [2022/44] | WO2020US65924 | Priority number, date | US201962952971P | 23.12.2019 Original published format: US 201962952971 P | US202063007489P | 09.04.2020 Original published format: US 202063007489 P | US202062704879P | 01.06.2020 Original published format: US 202062704879 P | [2022/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021133660 | Date: | 01.07.2021 | Language: | EN | [2021/26] | Type: | A1 Application with search report | No.: | EP4081805 | Date: | 02.11.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.07.2021 takes the place of the publication of the European patent application. | [2022/44] | Search report(s) | International search report - published on: | EP | 01.07.2021 | Classification | IPC: | G01N33/68, A61P7/04, C07K16/18 | [2022/44] | CPC: |
G01N33/6893 (EP);
C07K16/18 (EP,US);
A61K9/0019 (US);
A61P7/00 (US);
A61P7/04 (EP);
A61K2039/505 (EP);
A61K2039/54 (EP);
A61K2039/545 (EP);
C07K2317/526 (EP,US);
C07K2317/565 (US);
C07K2317/72 (EP);
C07K2317/92 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/44] | Title | German: | VERFAHREN ZUR BEHANDLUNG VON SCHWANGERSCHAFTSBEDINGTEM ATYPISCHEM HÄMOLYTISCH-URÄMISCHEM SYNDROM UNTER VERWENDUNG EINES ANTI-C5-ANTIKÖRPERS | [2022/44] | English: | METHODS OF TREATING PREGNANCY-ASSOCIATED ATYPICAL HEMOLYTIC UREMIC SYNDROME USING AN ANTI-C5 ANTIBODY | [2022/44] | French: | MÉTHODES DE TRAITEMENT DU SYNDROME URÉMIQUE HÉMOLYTIQUE ATYPIQUE ASSOCIÉ À LA GROSSESSE À L'AIDE D'UN ANTICORPS ANTI-C5 | [2022/44] | Entry into regional phase | 16.06.2022 | National basic fee paid | 16.06.2022 | Designation fee(s) paid | 16.06.2022 | Examination fee paid | Examination procedure | 16.06.2022 | Examination requested [2022/44] | 16.06.2022 | Date on which the examining division has become responsible | 04.04.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 27.12.2022 | Renewal fee patent year 03 | 27.12.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2019084438 (ALEXION PHARMA INC [US]) [X] 1-32,36-39 * p 97, last lines; p 115, l 9-10; p 212, l 5 ff;p 4, para 1;; claims 2, 7-16,18, 20,21,23-25, 32-36, 38-40,42 *; | [XI]WO2019236345 (ALEXION PHARMA INC [US]) [X] 1-15,17-19,22,23,25-27,30,36-39 * p 2, last para and 83-85 of the description; p 3, para 4;; claims 2-7, 12-16,19,20, 24,25,28-34 *[I] 33-35; | [X] - DOUGLAS SHERIDAN ET AL, "Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action", PLOS ONE, (20180412), vol. 13, no. 4, doi:10.1371/journal.pone.0195909, page e0195909, XP055611308 [X] 37-39 * abstract * DOI: http://dx.doi.org/10.1371/journal.pone.0195909 | by applicant | US6355245 | US8088376 | US8241628 | US8883158 | US9079949 | US2016176954 | US2017355757 | - CAPRIOLI et al., Blood, (20060000), vol. 108, pages 1267 - 1279 | - ESPARZA-GORDILLO et al., Hum Mol Genet, (20050000), vol. 14, pages 703 - 712 | - SAAD et al., AJP Reports, (20160000), vol. 6, no. 1 | - FAKHOURI F et al., J. Am. Soc. Nephrol., (20100000), vol. 21, no. 5, pages 859 - 867 | - FUKUZAWA T et al., Sci. Rep., (20170000), vol. 7, page 1080 | - CHOTHIA et al., Nature, (19890000), vol. 342, pages 877 - 83 | - THOMAS et al., Mol. Immunol., (19960000), vol. 33, pages 1389 - 401 | - DALL'ACQUA, W et al., J. Biol. Chem., (20060000), vol. 281, pages 23514 - 24 | - HINTON, P et al., J. Biol. Chem., (20040000), vol. 279, pages 6213 - 6 | - HINTON, P et al., J. Immunol., vol. 176, pages 346 - 56 | - PETKOVA, S et al., Int. Immunol., (20060000), vol. 18, pages 1759 - 69 | - DATTA-MANNAN, A et al., J. Biol. Chem., (20070000), vol. 282, pages 1709 - 17 | - KOHLER, G.MILSTEIN, C., Eur. J. Immunol., (19760000), vol. 6, pages 511 - 9 | - HUSE, W et al., Science, (19890000), vol. 246, pages 1275 - 81 | - KAPLAN et al., "Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura", Informa Health Care, (19920000), ISBN ISBN 0824786637 | - BRESLIN et al., Clin Am Soc Nephrol, (20060000), vol. 1, pages 88 - 99 | - GOICOECHEA DE JORGE et al., Proc Natl Acad Sci USA, (20070000), vol. 104, pages 240 - 245 | - ELABD et al., BMJ Case Rep, (20190000), vol. 12 | - THURMAN et al., Clin J Am Soc Nephrol, (20180000), vol. 13, pages 933 - 936 | WO1995US05688 | WO2007US06606 | WO2015US19225 |